PDCD1 and neoplasm: Interestingly, the present study complements the study of Guyon et al. (2020) [13], showing that exomiR-4315 from lymphocytes exposed to anti-PD-1 therapy is a source of resistance in tumor cells receiving this exomiR via regulation of the pro-apoptotic protein Bim.